Platelet Activating Factor Antagonist Design: Structure of Methyl Trans-5-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-2-oxo-4- Furancarboxylate
Overview
Authors
Affiliations
C14H16O6, Mr = 280.28, monoclinic, P2(1)/c, a = 6.070 (2), b = 9.526 (5), c = 22.418 (5) A, beta = 94.32 (2) degrees, V = 1293 A3, Z = 4, Dx = 1.44 g cm-3, lambda(Mo K alpha) = 0.71073 A, mu = 0.71 cm-1, F(000) = 592, T = 293 K, final R = 0.043 for 1400 observed [F0 greater than or equal to 5 sigma(F0)] reflections. The observed structure confirms a trans stereorelationship for the two substituents and an envelope conformation for the lactone ring. There is no crystallographically imposed symmetry. An analysis of the closest contacts in the cell lattice reveals two types of intermolecular interactions for this compound.
Lu P, Kung F, Kuo S, Chueh S, Guh J Naunyn Schmiedebergs Arch Pharmacol. 2006; 374(3):223-33.
PMID: 17102938 DOI: 10.1007/s00210-006-0114-x.
Genomic Relatedness of Xanthomonas campestris Strains Causing Diseases of Citrus.
Egel D, Graham J, Stall R Appl Environ Microbiol. 1991; 57(9):2724-30.
PMID: 16348555 PMC: 183647. DOI: 10.1128/aem.57.9.2724-2730.1991.
Leite Jr R, Egel D, Stall R Appl Environ Microbiol. 1994; 60(4):1078-86.
PMID: 7912499 PMC: 201442. DOI: 10.1128/aem.60.4.1078-1086.1994.